Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07806916) titled 'Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barre Syndrome(GREAT)' on Sept. 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).

Primary Sponsor: Beijing Tiantan Hospital

Condition: Guillain-Barre Syndrome

Intervention: Drug: Intravenous immunoglobulin (IVIG)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 2026

Target Sample Size: 110

To know more, visit https://clinicaltrials.gov/study/NCT07806916

Disclaimer: Curated by HT...